AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12601105
Drug: Persistent NAb+
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Persistent NAb+ (neutralizing antibodies positive)
Trial: 12601105
Drug: NAb- (neutralizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NAb- (neutralizing antibodies negative)
Trial: 1854617
Drug: Low 6‐mercaptopurine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low 6‐mercaptopurine (6‐MP) doses due to neutropaenia and higher doses of Mtx
Trial: 1854617
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy in maximally tolerated doses
Trial: 6147940
Drug: beta 1‐blockade
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta 1‐blockade (100 mg metoprolol)
Trial: 6147940
Drug: beta 1/2‐blockade
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta 1/2‐blockade (2 mg levobunolol)
Trial: 30777651
Drug: OnabotulinumtoxinA (BoNT)
RxNorm normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: OnabotulinumtoxinA (BoNT) prior to cognitive behavioral therapy (CBT)
Trial: 30777651
Drug: Placebo prior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo prior to cognitive behavioral therapy (CBT)
Trial: 26702121
Drug: 2000 IU
RxNorm normalized name: D 2000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 IU daily oral vitamin D3 supplementation
Trial: 26702121
Drug: 1000 IU
RxNorm normalized name: D 1000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 IU daily oral vitamin D3 supplementation
Trial: 15845315
Drug: Combined Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Cognitive Behavioral Therapy and Contingency Management (CBT+CM)
Trial: 15845315
Drug: Culturally Tailored
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally Tailored Cognitive Behavioral Therapy (GCBT)
Trial: 12821551
Drug: Electrophysiologically (EP)‐guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrophysiologically (EP)‐guided therapy
Trial: 12821551
Drug: No EP‐guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No EP‐guided therapy
Trial: 12821551
Drug: No EP-guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No EP-guided therapy
Trial: 12821551
Drug: Serial EP-guided
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serial EP-guided drug testing
Trial: 10382127
Drug: Colloidal bismuth
RxNorm normalized name: Colloidal bismuth subcitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloidal bismuth subcitrate (CBS) triple therapy
Trial: 10382127
Drug: Colloidal bismuth
RxNorm normalized name: Colloidal bismuth subcitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloidal bismuth pectin (CBP) triple therapy
Trial: 10382127
Drug: CBS quadruple
RxNorm normalized name: BroveX CB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBS quadruple therapy
Trial: 10382127
Drug: CBP quadruple
RxNorm normalized name: CBPC
DrugBank: Carbenicillin (DB00578)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CBP quadruple therapy
Trial: 8916625
Drug: No-couples-treatment control
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-couples-treatment control group
Trial: 1919540
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human interferon‐gamma (rIFN gamma) 0.1 mg/m2 intramuscularly thrice weekly for 16 weeks
Trial: 1919540
Drug: no anti‐viral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no anti‐viral therapy (controls)
Trial: 31033141
Drug: Wilms' tumor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wilms' tumor 1 peptide‐loaded dendritic cells (DCs) and OK‐432 adjuvant combined with conventional chemotherapy
Trial: 21712700
Drug: Pirfenidone (PFD)
RxNorm normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pirfenidone (PFD) 1800 mg/day for 6 months
Trial: 17123214
Drug: Multidisciplinary in‐patient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary in‐patient treatment programme
Trial: 17123214
Drug: Multidisciplinary functional
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary functional restoration treatment for patients with high risk of chronification
Trial: 11573589
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid enriched solution (AMIPAREN) infusion at a rate of 166 kJ h(‐1) in AA-PTC group
Trial: 11573589
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid enriched solution (AMIPAREN) infusion at a rate of 166 kJ h(‐1) in AA-TOF group
Trial: 11573589
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid enriched solution (AMIPAREN) infusion in AA-PTC group
Trial: 11573589
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid enriched solution (AMIPAREN) infusion in AA-TOF group
Trial: 8332615
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose cocaine (2 mg/kg)
Trial: 8332615
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose cocaine (1 mg/kg)
Trial: 27196998
Drug: Pre-hospital ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-hospital ticagrelor 180 mg loading dose
Trial: 27196998
Drug: In-hospital ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In-hospital ticagrelor 180 mg loading dose
Trial: 18251358
Drug: Vaginal estradiol
RxNorm normalized name: estradiol Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal estradiol cream
Trial: 12845387
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba (GB) therapy, 80 mg three times daily
Trial: 1458890
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg gemeprost as a vaginal pessary
Trial: 1458890
Drug: Treatment in
RxNorm normalized name: Other agents for local oral treatment in ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment in the sitting-room
Trial: 1458890
Drug: Treatment in
RxNorm normalized name: Other agents for local oral treatment in ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment in the ward
Trial: 1458890
Drug: Overall satisfaction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall satisfaction with method of treatment
Trial: 1458890
Drug: Preference to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preference to stay in hospital after administration of prostaglandin
Trial: 29633139
Drug: Response by
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Response by method of PRO administration
Trial: 27511452
Drug: Testosterone (T)
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone (T) administration
Trial: 23489530
Drug: Insulin resistance
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin resistance (HOMA >1.24)
Trial: 23489530
Drug: Insulin resistance
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin resistance (HOMA <1.24)
Trial: 16166441
Drug: 2-methoxyestradiol 1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-methoxyestradiol 1,200 mg/d
Trial: 16166441
Drug: 2-methoxyestradiol 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-methoxyestradiol 400 mg/d
Trial: 15709726
Drug: STA-MCA anastomosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STA-MCA anastomosis combined with best medical therapy
Trial: 10588962
Drug: Immediate antiandrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate antiandrogen therapy (goserelin or bilateral orchiectomy)
Trial: 8759656
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg b.i.d.
Trial: 15298636
Drug: Omeprazole 80
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole 80 mg/day
Trial: 30576544
Drug: Netupitant 30
RxNorm normalized name: netupitant 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Netupitant 30 mg
Trial: 26511056
Drug: Bone marrow
RxNorm normalized name: bone marrow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone marrow derived mononuclear cell (BMMNC) administration
Trial: 19678774
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba L. tablets (40 mg leaf extracts), taken three times a day from the 16th day of the menstrual cycle to the 5th day of the next cycle.
Trial: 17183512
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received conventional treatment (corticosteroid injections, stretching, or no intervention).
Trial: 15334379
Drug: Pancreas Tonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancreas Tonic (2 capsules 3 times a day) for 3 months
Trial: 9274439
Drug: exemestane 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: exemestane 0.5 mg
Trial: 9274439
Drug: exemestane 1
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: exemestane 1 mg
Trial: 9274439
Drug: exemestane 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: exemestane 2.5 mg
Trial: 9274439
Drug: exemestane 5
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: exemestane 5 mg
Trial: 9274439
Drug: exemestane (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: exemestane (all doses)
Trial: 7686279
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous infusion (mode A)
Trial: 7686279
Drug: Continuous basal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous basal rate subcutaneous infusion + PCA (mode B)
Trial: 27510536
Drug: Drinking 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drinking 300 mL H2O during the 4-hour period
Trial: 23175912
Drug: Dance Movement
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dance Movement Therapy (DMT), 2 times a week for 4 weeks
Trial: 20631559
Drug: Atypical antipsychotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atypical antipsychotic agents (especially clozapine) in patients with comorbid psychosis (DD)
Trial: 20631559
Drug: Atypical antipsychotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atypical antipsychotic agents in patients without comorbid psychosis (SD)
Trial: 18202708
Drug: Dorzolamide 2%
RxNorm normalized name: Brimonidine Tartrate 0.1%, Dorzolamide 2% Ophthalmic drops, solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorzolamide 2% monotherapy
Trial: 18202708
Drug: Timolol 0.50%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol 0.50% monotherapy
Trial: 18202708
Drug: Dorzolamide/timolol fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorzolamide/timolol fixed combination
Trial: 10344454
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg day(‐1) vitamin E supplementation for 28 days
Trial: 31024092
Drug: High dairy
RxNorm normalized name: Beano Dairy Defense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dairy condition (four daily servings of whole milk or full-fat dairy products)
Trial: 28118425
Drug: Glutamate injections
RxNorm normalized name: glutamate
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Glutamate injections
Trial: 28118425
Drug: Glutamate injections
RxNorm normalized name: glutamate
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Glutamate injections with 0.5 kg and 1.0 kg pressure
Trial: 25501607
Drug: Lipid-based nutritional
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-based nutritional supplements with added vitamins and minerals (LNS-VM)
Trial: 25501607
Drug: Lipid-based nutritional
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-based nutritional supplements without added vitamins and minerals (LNS)
Trial: 24602760
Drug: Maintenance rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Maintenance rituximab (rituximab 375 mg/m² weekly for 4 weeks followed by 12 infusions at 2-month intervals for 2 years)
Trial: 24602760
Drug: Rituximab induction
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab induction (rituximab 375 mg/m² weekly for 4 weeks)
Trial: 19774308
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A mixed with 2 ml saline
Trial: 19774308
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A mixed with 8 ml saline
Trial: 11277343
Drug: Hairgain (active
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hairgain (active preparation)
Trial: 9533060
Drug: Eprosartan 400
RxNorm normalized name: eprosartan 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eprosartan 400 mg alone
Trial: 9533060
Drug: Eprosartan 400
RxNorm normalized name: eprosartan 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eprosartan 400 mg with ranitidine 150 mg after 3 days of ranitidine 150 mg twice daily
Trial: 8029793
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH) - ardeparin
Trial: 8029793
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH) - 4 different LMWHs
Trial: 28693854
Drug: bOPV and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bOPV and one dose of IPV
Trial: 28693854
Drug: bOPV and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bOPV and two doses of IPV
Trial: 25711726
Drug: Diazepam 10.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 10.0 mg
Trial: 19653786
Drug: Cocaine (175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine (175 mg, p.o.; 5 hourly doses; 875 mg/day)
Trial: 16442902
Drug: Low-dose warfarin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose warfarin or placebo
Trial: 16442902
Drug: Lovastatin in
RxNorm normalized name: Product containing lovastatin in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin in low or high doses
Trial: 8290902
Drug: Ceftazidime 2
RxNorm normalized name: ceftazidime 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime 2 g bid
Trial: 8360130
Drug: Imipenem/cilastatin 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem/cilastatin 0.5 g qid
Trial: 3098997
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy thrice weekly (PT3)
Trial: 3098997
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy five times weekly (PT5)
Trial: 3098997
Drug: No therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No therapy (controls)
Trial: 31526206
Drug: Cabergoline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline (1 mg)
Trial: 29211123
Drug: External Hexagon
RxNorm normalized name: CATHETER,EXTERNAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External Hexagon (EH) implants
Trial: 27353076
Drug: Morse-Taper (MT)
RxNorm normalized name: caper berry extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morse-Taper (MT) implants
Trial: 15486152
Drug: Therapeutic Touch
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic Touch (20 minutes daily for 7 days)
Trial: 15486152
Drug: Shared activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shared activity with a registered nurse (20 minutes daily for 7 days)
Trial: 29882388
Drug: Immunotherapy treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy treatments with various doses (specific dosages not mentioned)
Trial: 29882388
Drug: Safe doses
RxNorm normalized name: Safe-Guard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safe doses identified in the first stage of the trial
Trial: 24341527
Drug: 0.03 mg
RxNorm normalized name: biotin 0.03 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03 mg MRrhTSH
Trial: 24341527
Drug: 0.01 mg
RxNorm normalized name: urea 0.01 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.01 mg MRrhTSH
Trial: 24341527
Drug: 0.03 mg
RxNorm normalized name: biotin 0.03 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03 mg MRrhTSH (subgroup with basal (131)I uptake <20%)
Trial: 24341527
Drug: 0.01 mg
RxNorm normalized name: urea 0.01 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.01 mg MRrhTSH (subgroup)
Trial: 9510281
Drug: Cilostazol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilostazol (100 mg b.i.d.)
Trial: 3394980
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg IM butorphanol
Trial: 3394980
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg IM morphine
Trial: 31811010
Drug: Internet-based warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based warfarin anticoagulation management model
Trial: 28943074
Drug: Conventional fractionated
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional fractionated radiation therapy (78 Gy in 39 fractions)
Trial: 28943074
Drug: Hypofractionated radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypofractionated radiation therapy (64.6 Gy in 19 fractions)
Trial: 23301875
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 (400 mg) and selenium (200 μg) supplementation for 12 weeks
Trial: 16752942
Drug: ASA 500
RxNorm normalized name: ASA 500 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASA 500 mg
Trial: 16752942
Drug: ASA +
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ASA + EGb 761 240 mg
Trial: 15087629
Drug: Intrathecal analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal analgesia (bupivacaine 15 mg, clonidine 75 microg, morphine 0.2 mg)
Trial: 15087629
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia supplemented with intravenous fentanyl
Trial: 11576197
Drug: rizatriptan ODT
DrugBank: Rizatriptan (DB00953)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rizatriptan ODT 10-mg
Trial: 9767742
Drug: Preoperative erythropoietin
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative erythropoietin therapy with acute normovolemic hemodilution
Trial: 8144779
Drug: Active drug
RxNorm normalized name: Capillary active drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active drug and Placebo
Trial: 8144779
Drug: First drug
RxNorm normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First drug tested
Trial: 8144779
Drug: Second drug
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second drug tested
Trial: 2556484
Drug: Alfa LMWH
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alfa LMWH 7500 anti-Xa coagulometric units twice daily
Trial: 30891605
Drug: Intermittent preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent preventive treatment of malaria in pregnancy (IPTp)
Trial: 19843681
Drug: Never used
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Never used postmenopausal hormones
Trial: 16798698
Drug: Metronidazole 750
RxNorm normalized name: metronidazole 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 750 mg 3 times daily + S. boulardii 250 mg b.i.d. orally for 10 days
Trial: 16798698
Drug: Metronidazole 750
RxNorm normalized name: metronidazole 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 750 mg 3 times daily + placebo (empty capsules) for 10 days